Comparison

Tirzepatide vs Cagrilintide: Evidence-Based Comparison

Compare Tirzepatide and Cagrilintide: dosing, mechanisms, safety profiles, and research evidence. Citation-backed comparison.

Overview

A comparison of Tirzepatide and Cagrilintide in metabolic and weight research, including receptor targets, mechanism differences, and current evidence.

Compared compounds

Tirzepatide Cagrilintide

Overview

Tirzepatide and Cagrilintide represent different approaches to metabolic intervention. Tirzepatide is a dual GIP/GLP-1 receptor agonist with an established clinical evidence base, while Cagrilintide is a long-acting amylin analog studied for its complementary mechanism in satiety and weight regulation, including in combination with Semaglutide in the CagriSema trial program.

Mechanism Comparison

Tirzepatide works primarily through the incretin axis, activating both GLP-1 and GIP receptors to regulate insulin secretion, satiety, and gastric emptying. Cagrilintide acts through amylin receptors, which are separate from the incretin pathway, producing satiety through a different neurological mechanism. This mechanistic distinction makes Cagrilintide more interesting as a complement to GLP-1 compounds than as a direct substitute.

Dosing and Protocol Comparison

Tirzepatide is studied at weekly subcutaneous doses in a titration protocol from 2.5 mg to 15 mg. Cagrilintide is studied at weekly doses from 0.3 mg to 4.5 mg as a monotherapy or in the CagriSema combination. Because their mechanisms are complementary rather than overlapping, the more meaningful protocol comparison is Tirzepatide monotherapy versus CagriSema combination rather than Tirzepatide versus Cagrilintide alone.

Evidence Comparison

Tirzepatide has a substantially more mature evidence base including the SURMOUNT and SURPASS trial programs with strong weight and glycemic outcome data. Cagrilintide is newer in clinical development, with most published data coming from the CagriSema combination trial program. Head-to-head evidence between these two compounds specifically is limited, as they target different metabolic axes.

Frequently asked questions

Which is better, Tirzepatide or Cagrilintide?

Tirzepatide and Cagrilintide are researched for different contexts, so the better choice depends on study goals, mechanism priorities, and protocol design.

Can you stack Tirzepatide and Cagrilintide?

Some researchers evaluate Tirzepatide and Cagrilintide together, but combination design depends on evidence quality, safety considerations, and whether overlapping mechanisms are appropriate for the research question.